Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
PTC Therapeutics Inc(PTCT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PTCT
11/06/2026: PTCT (2-star) is currently NOT-A-BUY. Pass it for now.
PTC Therapeutics is a global biotechnology company focused on developing therapies for rare genetic disorders through RNA-binding and gene therapy platforms. Its strengths include a proven track record in regulatory environments and an established commercial presence for drugs like Emflaza and Upstaza. While the company provides significant growth potential via its innovative pipeline, it faces substantial risks including regulatory uncertainty for lead product Translarna and intense competition from major biotech firms. Investors should note the firm's lack of consistent profitability and should monitor clinical data readouts and regulatory decisions closely. This stock may suit investors willing to accept volatility in exchange for potential breakthroughs in rare disease treatments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential via its pipeline, but it is tempered by binary regulatory and clinical risks. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunities around major clinical trial data readouts or regulatory approvals. |
| Value investor | Weak fit | The lack of consistent profitability makes traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not pay a dividend and reinvests all capital into research. |
| Low-risk investor | Weak fit | Biotechnology firms at this stage inherently carry high risks related to clinical success and regulatory outcomes. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to binary clinical and regulatory news. |
| Valuation risk | Medium | Valuation is often based on long-term projections of future therapy adoption. |
| Competition risk (Rare disease therapeutics) | High | Competitors like Sarepta possess strong market positions in similar neuromuscular disease indications. |
| Business quality | Medium | While the platform is innovative, the firm has historically struggled to reach consistent GAAP profitability. |
| Dividend income | Low / none | Income-focused investors will not find this stock suitable. |
| Execution risk | High | Success depends on executing complex gene therapy rollouts and managing international regulatory hurdles. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 20.88% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.47B USD | Price to earnings Ratio - | 1Y Target Price 100.47 |
Price to earnings Ratio - | 1Y Target Price 100.47 | ||
Volume (30-day avg) 1.2M shares | Beta 0.51 | 52 Weeks Range 58.80 - 90.87 | Updated Date 11/08/2026 |
52 Weeks Range 58.80 - 90.87 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.47 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Products | Sales of Translarna, Emflaza, and Upstaza. | Revenue comes from selling specialized drugs to patients with rare genetic diseases. |
| Geographic Exposure | Operations in the U.S., Europe, and other international markets. | The company depends on global regulatory bodies to approve and reimburse its products in different countries. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 0.17 | Actual 0.61 |
Profitability
Profit Margin -9.17% | Operating Margin (TTM) 38.04% |
Management Effectiveness
Return on Assets (TTM) 5.31% | Return on Equity (TTM) -7740.12% |
Valuation
Trailing PE - | Forward PE 19.57 | Enterprise Value 3.97B | Price to Sales(TTM) 4.73 |
Enterprise Value 3.97B | Price to Sales(TTM) 4.73 | ||
Enterprise Value to Revenue 3.44 | Enterprise Value to EBITDA 22.76 | Shares Outstanding 83.54M | Shares Floating 73.77M |
Shares Outstanding 83.54M | Shares Floating 73.77M | ||
Percent Insiders 7.3 | Percent Institutions 119.92 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.